Follow the people · Insider
Peter Kaiser
Peter Kaiser files insider transactions with the SEC as a chief development officer of Ocular Therapeutix (OCUL). We hold 3 disclosed purchases and sales filed since 4 October 2024, 1 of them in the last 90 days.
- Files forOCUL
- Disclosed buys and sells3 in all, 1 in the last 90 days
- Last disclosure26 August 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 2 October 2024 — 24 August 2026Chief Development Officer · Ocular Therapeutix (OCUL)16 Form 4 lines · source: SEC Form 4
Everything they disclosed
16 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 3,035 shares of Ocular TherapeutixSEC Form 426 August 2026Common Stock · traded 24 August 2026 · filed 26 August 2026
- ▼ sold on the open market 2,967 shares of Ocular TherapeutixSEC Form 428 May 2026Common Stock · traded 26 May 2026 · filed 28 May 2026
- ▼ sold on the open market 2,810 shares of Ocular TherapeutixSEC Form 425 February 2026Common Stock · traded 23 February 2026 · filed 25 February 2026
- ▼ sold on the open market 2,810 shares of Ocular TherapeutixSEC Form 425 February 2026Common Stock · traded 23 February 2026 · filed 25 February 2026
- was granted 79,112 shares of Ocular TherapeutixSEC Form 46 January 2026Common Stock · traded 2 January 2026 · filed 6 January 2026
- was granted 240,932 shares of Ocular Therapeutix (a derivative holding)SEC Form 46 January 2026Stock Option (Right to Buy) · traded 2 January 2026 · filed 6 January 2026
- was granted 240,932 shares of Ocular Therapeutix (a derivative holding)SEC Form 46 January 2026Stock Option (Right to Buy) · traded 2 January 2026 · filed 6 January 2026
- was granted 79,112 shares of Ocular TherapeutixSEC Form 46 January 2026Common Stock · traded 2 January 2026 · filed 6 January 2026
- ▼ sold on the open market 3,007 shares of Ocular TherapeutixSEC Form 426 November 2025Common Stock · traded 24 November 2025 · filed 26 November 2025
- ▼ sold on the open market 9,653 shares of Ocular TherapeutixSEC Form 46 October 2025Common Stock · traded 2 October 2025 · filed 6 October 2025
- ▼ sold on the open market 3,011 shares of Ocular TherapeutixSEC Form 427 August 2025Common Stock · traded 25 August 2025 · filed 27 August 2025
- ▼ sold on the open market 2,974 shares of Ocular TherapeutixSEC Form 427 May 2025Common Stock · traded 23 May 2025 · filed 27 May 2025
- ▼ sold on the open market 3,009 shares of Ocular TherapeutixSEC Form 426 February 2025Common Stock · traded 24 February 2025 · filed 26 February 2025
- ▼ sold on the open market 2,897 shares of Ocular TherapeutixSEC Form 427 November 2024Common Stock · traded 25 November 2024 · filed 27 November 2024
- was granted 200,000 shares of Ocular Therapeutix (a derivative holding)SEC Form 44 October 2024Stock Option (Right to Buy) · traded 2 October 2024 · filed 4 October 2024
- was granted 100,000 shares of Ocular TherapeutixSEC Form 44 October 2024Common Stock · traded 2 October 2024 · filed 4 October 2024
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.